Cargando…

Clinical Efficacy of Alprostadil Combined with α-lipoic Acid in the Treatment of Elderly Patients with Diabetic Nephropathy

OBJECTIVE: To evaluate the effect and toxicity of alprostadil combined with thioctic acid injection in the treatment of patients with diabetic nephropathy (DN). METHODS: Sixty two patients with DN were included in this study and randomly divided into control group (n=32) and experiment group (n=30)....

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Yan, Peng, Jianyun, Cai, Xiaoping, Zhang, Xiaoru, Liao, Yifei, Lan, Lejian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter Open 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5639393/
https://www.ncbi.nlm.nih.gov/pubmed/29043297
http://dx.doi.org/10.1515/med-2017-0046
_version_ 1783270873318293504
author Hong, Yan
Peng, Jianyun
Cai, Xiaoping
Zhang, Xiaoru
Liao, Yifei
Lan, Lejian
author_facet Hong, Yan
Peng, Jianyun
Cai, Xiaoping
Zhang, Xiaoru
Liao, Yifei
Lan, Lejian
author_sort Hong, Yan
collection PubMed
description OBJECTIVE: To evaluate the effect and toxicity of alprostadil combined with thioctic acid injection in the treatment of patients with diabetic nephropathy (DN). METHODS: Sixty two patients with DN were included in this study and randomly divided into control group (n=32) and experiment group (n=30). Patients in the control group were given alprostadil 20ug+NS 100ml ivgtt, qd and patients in the experiment group were given alprostadil 20ug+NS 100ml ivgtt combined with thioctic acid injection of 0.45g+100ml ivgtt, qd for 14 days. After treatment, the renal function and serum level of CRP, IL-6 and TNF-α were compared between the two groups. RESULTS: After two weeks of treatment, the serum level of CysC and UAER significant decreased for both control and experiment group with statistical difference of p<0.05. After treatment, the serum level of CysC were 1.40 ±0.46 mg/L and 1.02±0.33 for control and experiment group respectively (p<0.05). The post-treatment UAER in experiment group was significantly lower than those of control group with statistical difference (81.02±0.33 vs112.45±20.32, p<0.05) ug/min. The serum level of CRP, IL-6 and TNF-α were significantly decreased after treatment for both control and experiment group (p<0.05). And the post-treatment serum CRP, IL-6 and TNF-α in experiment group were significantly lower than those of control group with statistical difference (p<0.05). No significant side effects were found for the two groupsin the course of treatment. CONCLUSION: Alprostadil combined with α-lipoic acid may improve renal function in patients with diabetic nephropathy by decreasing the levels of serum inflammatory factors.
format Online
Article
Text
id pubmed-5639393
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher De Gruyter Open
record_format MEDLINE/PubMed
spelling pubmed-56393932017-10-17 Clinical Efficacy of Alprostadil Combined with α-lipoic Acid in the Treatment of Elderly Patients with Diabetic Nephropathy Hong, Yan Peng, Jianyun Cai, Xiaoping Zhang, Xiaoru Liao, Yifei Lan, Lejian Open Med (Wars) Regular Articles OBJECTIVE: To evaluate the effect and toxicity of alprostadil combined with thioctic acid injection in the treatment of patients with diabetic nephropathy (DN). METHODS: Sixty two patients with DN were included in this study and randomly divided into control group (n=32) and experiment group (n=30). Patients in the control group were given alprostadil 20ug+NS 100ml ivgtt, qd and patients in the experiment group were given alprostadil 20ug+NS 100ml ivgtt combined with thioctic acid injection of 0.45g+100ml ivgtt, qd for 14 days. After treatment, the renal function and serum level of CRP, IL-6 and TNF-α were compared between the two groups. RESULTS: After two weeks of treatment, the serum level of CysC and UAER significant decreased for both control and experiment group with statistical difference of p<0.05. After treatment, the serum level of CysC were 1.40 ±0.46 mg/L and 1.02±0.33 for control and experiment group respectively (p<0.05). The post-treatment UAER in experiment group was significantly lower than those of control group with statistical difference (81.02±0.33 vs112.45±20.32, p<0.05) ug/min. The serum level of CRP, IL-6 and TNF-α were significantly decreased after treatment for both control and experiment group (p<0.05). And the post-treatment serum CRP, IL-6 and TNF-α in experiment group were significantly lower than those of control group with statistical difference (p<0.05). No significant side effects were found for the two groupsin the course of treatment. CONCLUSION: Alprostadil combined with α-lipoic acid may improve renal function in patients with diabetic nephropathy by decreasing the levels of serum inflammatory factors. De Gruyter Open 2017-10-05 /pmc/articles/PMC5639393/ /pubmed/29043297 http://dx.doi.org/10.1515/med-2017-0046 Text en © 2017 Yan Hong et al. http://creativecommons.org/licenses/by-nc-nd/3.0 This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
spellingShingle Regular Articles
Hong, Yan
Peng, Jianyun
Cai, Xiaoping
Zhang, Xiaoru
Liao, Yifei
Lan, Lejian
Clinical Efficacy of Alprostadil Combined with α-lipoic Acid in the Treatment of Elderly Patients with Diabetic Nephropathy
title Clinical Efficacy of Alprostadil Combined with α-lipoic Acid in the Treatment of Elderly Patients with Diabetic Nephropathy
title_full Clinical Efficacy of Alprostadil Combined with α-lipoic Acid in the Treatment of Elderly Patients with Diabetic Nephropathy
title_fullStr Clinical Efficacy of Alprostadil Combined with α-lipoic Acid in the Treatment of Elderly Patients with Diabetic Nephropathy
title_full_unstemmed Clinical Efficacy of Alprostadil Combined with α-lipoic Acid in the Treatment of Elderly Patients with Diabetic Nephropathy
title_short Clinical Efficacy of Alprostadil Combined with α-lipoic Acid in the Treatment of Elderly Patients with Diabetic Nephropathy
title_sort clinical efficacy of alprostadil combined with α-lipoic acid in the treatment of elderly patients with diabetic nephropathy
topic Regular Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5639393/
https://www.ncbi.nlm.nih.gov/pubmed/29043297
http://dx.doi.org/10.1515/med-2017-0046
work_keys_str_mv AT hongyan clinicalefficacyofalprostadilcombinedwithalipoicacidinthetreatmentofelderlypatientswithdiabeticnephropathy
AT pengjianyun clinicalefficacyofalprostadilcombinedwithalipoicacidinthetreatmentofelderlypatientswithdiabeticnephropathy
AT caixiaoping clinicalefficacyofalprostadilcombinedwithalipoicacidinthetreatmentofelderlypatientswithdiabeticnephropathy
AT zhangxiaoru clinicalefficacyofalprostadilcombinedwithalipoicacidinthetreatmentofelderlypatientswithdiabeticnephropathy
AT liaoyifei clinicalefficacyofalprostadilcombinedwithalipoicacidinthetreatmentofelderlypatientswithdiabeticnephropathy
AT lanlejian clinicalefficacyofalprostadilcombinedwithalipoicacidinthetreatmentofelderlypatientswithdiabeticnephropathy